OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non–Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib
Natalie Mausey, Zachery Halford
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 6, pp. 622-635
Closed Access | Times Cited: 8
Natalie Mausey, Zachery Halford
Annals of Pharmacotherapy (2023) Vol. 58, Iss. 6, pp. 622-635
Closed Access | Times Cited: 8
Showing 8 citing articles:
Impact of KRAS mutation on the tumor microenvironment in colorectal cancer
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 7
Yiru Zhou, Yeye Kuang, Chan Wang, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 5, pp. 1947-1964
Open Access | Times Cited: 7
Phytoactive-Loaded Lipid Nanocarriers for Simvastatin Delivery: A Drug Repositioning Strategy Against Lung Cancer
Rocío Celeste Gambaro, Cecilia Y. Chain, Sebastián Scioli Montoto, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 255-255
Open Access
Rocío Celeste Gambaro, Cecilia Y. Chain, Sebastián Scioli Montoto, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 255-255
Open Access
Tumour-agnostic kinase inhibitors
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
Jacob J. Adashek, Mina Nikanjam, Razelle Kurzrock
Nature Reviews Drug Discovery (2025)
Closed Access
Development of PROTACS degrading KRAS and SOS1
Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1257-1264
Open Access | Times Cited: 2
Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1257-1264
Open Access | Times Cited: 2
Protocol to perform fragment screening using NMR spectroscopy
Qiwei Huang, CongBao Kang
STAR Protocols (2024) Vol. 5, Iss. 3, pp. 103278-103278
Open Access
Qiwei Huang, CongBao Kang
STAR Protocols (2024) Vol. 5, Iss. 3, pp. 103278-103278
Open Access
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Ki Lui, Kwok‐Kuen Cheung, Winnie Wing Man Ng, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11954-11954
Open Access
Ki Lui, Kwok‐Kuen Cheung, Winnie Wing Man Ng, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 11954-11954
Open Access
A novel injectable nanotherapeutic platform increasing the bioavailability and antitumor efficacy of Arachidonoylcyclopropylamide on an ectopic non-small cell lung cancer xenograft model: A randomized controlled trial
Özge Boyacıoğlu, Cem Varan, Erem Bilensoy, et al.
International Journal of Pharmaceutics (2024), pp. 125153-125153
Closed Access
Özge Boyacıoğlu, Cem Varan, Erem Bilensoy, et al.
International Journal of Pharmaceutics (2024), pp. 125153-125153
Closed Access
KRAS-Degrading Compounds: A Novel Approach to Treat Cancer by Targeting Both Wild-Type and Mutated KRAS Forms
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 11, pp. 1493-1495
Closed Access
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 11, pp. 1493-1495
Closed Access
